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Hypoxia is an important contributor to the heterogeneity of the microenvironment
of solid tumors and is a significant environmental stressor that drives adaptations
which are essential for the survival and metastatic capabilities of tumor cells. Critical
adaptivemechanisms include alteredmetabolism, pH regulation, epithelial-mesenchymal
transition, angiogenesis, migration/invasion, diminished response to immune cells and
resistance to chemotherapy and radiation therapy. In particular, pH regulation by hypoxic
tumor cells, through the modulation of cell surface molecules such as extracellular
carbonic anhydrases (CAIX and CAXII) and monocarboxylate transporters (MCT-1 and
MCT-4) functions to increase cancer cell survival and enhance cell invasion while also
contributing to immune evasion. Indeed, CAIX is a vital regulator of hypoxia mediated
tumor progression, and targeted inhibition of its function results in reduced tumor growth,
metastasis, and cancer stem cell function. However, the integrated contributions of the
repertoire of hypoxia-induced effectors of pH regulation for tumor survival and invasion
remain to be fully explored and exploited as therapeutic avenues. For example, the
clinical use of anti-angiogenic agents has identified a conundrum whereby this treatment
increases hypoxia and cancer stem cell components of tumors, and accelerates
metastasis. Furthermore, hypoxia results in the infiltration of myeloid-derived suppressor
cells (MDSCs), regulatory T cells (Treg) and Tumor Associated Macrophages (TAMs),
and also stimulates the expression of PD-L1 on tumor cells, which collectively suppress
T-cell mediated tumor cell killing. Therefore, combinatorial targeting of angiogenesis, the
immune system and pH regulation in the context of hypoxia may lead to more effective
strategies for curbing tumor progression and therapeutic resistance, thereby increasing
therapeutic efficacy and leading to more effective strategies for the treatment of patients
with aggressive cancer.
Keywords: hypoxia, tumormicroenvironment, carbonic anhydrase IX,monocarboxylate transporter, angiogenesis,
immune checkpoint inhibitors
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INTRODUCTION
The tumor microenvironment (TME) is heterogeneous in
its composition and dynamic in its evolution. Hypoxia is a
prominent component of the TME of solid cancers and is a result
of an imbalance between the increasing demand for oxygen and
nutrients by rapidly proliferating tumor cells and an inadequate,
dysfunctional blood supply resulting from tumor angiogenesis
(Lendahl et al., 2009; Bailey et al., 2012). The presence of hypoxia
is an independent marker of poor prognosis in many types
of human cancer, including breast, non-small cell lung, head
and neck, ovarian and cervical cancer (Brahimi-Horn et al.,
2007; Semenza, 2014). Furthermore, hypoxia is a functional
contributor to several biological processes critical for cancer
progression, including angiogenesis, epithelial-mesenchymal
transition (EMT), migration/invasion, maintenance of cancer
stem cells (CSCs) and the associated CSC niche, metastasis,
immune surveillance and resistance to chemotherapy and
radiotherapy (Gillies et al., 2012; Parks et al., 2013). Thus,
it is not surprising that hypoxia is associated with reduced
patient survival in many cancers (Semenza, 2014). Importantly,
the development of hypoxia in the TME produces substantial
cellular stress that drives adaptive responses by cancer cells aimed
at providing advantages for survival, growth and metastasis
(Gatenby and Gillies, 2008; Kroemer and Pouyssegur, 2008;
Damaghi et al., 2013; Marchiq and Pouysségur, 2015). Targeting
the molecular machinery necessary for driving these adaptations
is a critical strategy required for the development of effective
cancer therapy.
Role of Metabolic Reprogramming and
Angiogenesis in pH Dysregulation
Early in tumor development, cancer cells proliferate beyond
the limit of diffusion and confront hypoxia, resulting in the
inhibition of energy production by oxidative phosphorylation.
The increasing demand for energy in the form of ATP and
for anabolic precursors by rapidly proliferating cancer cells
in this low oxygen environment triggers rapid metabolic
reprogramming (Marchiq and Pouysségur, 2015). Tumor cells
undergo a “metabolic switch” and, through activation of HIF-
1α, shift toward increased use of glycolysis to efficiently
maintain cellular bioenergetics and macromolecular biosynthesis
in increasingly restrictive growth conditions (Pouyssegur et al.,
2006; Marchiq and Pouysségur, 2015). As a result of metabolic
reprogramming, cancer cells display increased heterogeneity in
glucose metabolism, investing most heavily, but not exclusively,
in glycolysis, while continuing to utilize glucose oxidation, albeit
at a reduced level in hypoxic regions (Sonveaux et al., 2008;
Hensley et al., 2016; Pavlova and Thompson, 2016). Furthermore,
it is now recognized that cancer cells use alternative carbon
sources, especially glutamine, to promote the tricarboxylic acid
(TCA) cycle (Sonveaux et al., 2008; Hensley et al., 2016;
Pavlova and Thompson, 2016). The perpetuation of a level of
oxidative phosphorylation in the hypoxic microenvironment
further reduces the amount of oxygen available, effectively
exacerbating hypoxia (Sonveaux et al., 2008; Hensley et al., 2016).
Importantly, glycolytic metabolism is associated with increased
metabolic plasticity, allows cancer cells to utilize glucose for
both energy and biosynthesis (Payen et al., 2015a,b), and fuels
the “Warburg effect” in which cancer cells maintain highly
glycolytic metabolism even in the presence of oxygen (Marchiq
and Pouysségur, 2015). However, a major consequence of the
switch to glycolytic metabolism by hypoxic cancer cells is the
production of acidic metabolites, including lactate and protons
(H+), which result in increased tumor acidosis and further
challenge cell survival (Brahimi-Horn et al., 2011; Webb et al.,
2011; Damaghi et al., 2013; Gillies and Gatenby, 2015).
In addition to regulating metabolic reprogramming, the
HIF-1-mediated transcriptional program induced by cancer
cells in hypoxia drives the process of tumor angiogenesis, a
hallmark of cancer progression (Hanahan and Weinberg, 2011).
Angiogenesis may be viewed as an initial attempt by the growing
tumor to alleviate hypoxia and provide vital nutrients and oxygen
to cancer cells (Kerbel, 2008; Rapisarda and Melillo, 2012; Welti
et al., 2013; McIntyre and Harris, 2015). However, in contrast to
the balanced, tightly regulated multistage process of angiogenesis
in normal tissues, tumor angiogenesis is aberrantly regulated
and leads to vessels that are tortuous, leaky and dysfunctional
(Kerbel, 2008; De Bock et al., 2011; Rapisarda and Melillo, 2012;
Welti et al., 2013). As a result, tumor tissues generally exhibit
poor perfusion and increased interstitial pressure, a situation
that leads to significant biological consequences, including the
further development of hypoxic regions, a reduction in nutrient
delivery and a reduced ability to remove rapidly accumulating
acidic metabolites from the TME (Gillies et al., 2012; Rapisarda
andMelillo, 2012). Therefore, the switch to glycolytic metabolism
by cancer cells and the angiogenic response to tumor hypoxia
collude to create an increasingly acidic, hypoxic TME that fuels
adaptations by tumor cells that are geared toward enhanced
survival and growth in an otherwise hostile environment.
TARGETING pH REGULATION AND
HYPOXIA-DRIVEN ACIDOSIS
A major ramification of the generation of large amounts of
acidic metabolites by glycolytic cancer cells, coupled with
impaired perfusion and diffusion capacity in hypoxia, is
increasing intracellular and extracellular acidosis (Webb et al.,
2011; Damaghi et al., 2013; McIntyre and Harris, 2015). The
accumulation of lactate and H+ in glycolytic cells, if left
unbuffered, leads to intracellular acidification and apoptosis
(Webb et al., 2011; Damaghi et al., 2013), while a slightly
alkaline intracellular pH (pHi) is permissive for proliferation
(Webb et al., 2011). In contrast, acidification of the TME
stimulates breakdown of the extracellular matrix, and promotes
migration, invasion and metastasis (Webb et al., 2011; Damaghi
et al., 2013). Therefore, to both mitigate the potentially lethal
consequences of increasing intracellular acidosis and exploit the
advantages of a hypoxic, acidic TME, cancer cells upregulate
the molecular machinery necessary to maintain a reverse pH
gradient (i.e., alkaline pHi and acidic pHe) that acts to promote
survival, proliferation, invasion and metastasis (Webb et al.,
2011; Damaghi et al., 2013). Key pH regulatory components that
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cancer cells upregulate in hypoxia include membrane-bound,
extracellular carbonic anhydrases (CAs), particularly CAIX
and CAXII, which maintain an intracellular and extracellular
acid-base balance (McDonald et al., 2012; Damaghi et al.,
2013; McDonald and Dedhar, 2014), and monocarboxylate
transporters (MCTs), especially MCT4, which facilitate lactate
extrusion (Marchiq and Pouysségur, 2015). The importance of
these factors in regulating pH in hypoxia has resulted in their
exploitation as therapeutic targets across a broad spectrum of
solid tumors, as discussed below.
Carbonic Anhydrase IX
Carbonic Anhydrase IX (CAIX) is a major effector of the
HIF-1-mediated transcriptional response to tumor hypoxia
and its critical role in tumor progression is well-recognized
(McDonald et al., 2012; McDonald and Dedhar, 2014; Pastorek
and Pastorekova, 2015). It is highly expressed in the hypoxic
regions of many types of solid tumors, has a very restricted
expression profile in normal tissues and is a well-established
marker of poor prognosis across a wide spectrum of solid cancers
(McDonald et al., 2012; Pastorek and Pastorekova, 2015). Of
importance for its utility as a cancer therapeutic target, CAIX is a
critical, hypoxia-induced functional effector of several biological
processes necessary for cancer growth and metastasis, including
pH regulation and cell survival, migration and invasion,
maintenance of cancer stem cell (CSC) function, development
of the pre-metastatic niche and acquisition of chemo and
radioresistant properties (McDonald et al., 2012; McDonald
and Dedhar, 2014; Chafe and Dedhar, 2015; Pastorek and
Pastorekova, 2015). By catalyzing the reversible hydration of CO2
to bicarbonate (HCO−3 ) and protons (H
+) at the extracellular
surface (Gillies et al., 2008; McDonald et al., 2012; Parks et al.,
2013; Sedlakova et al., 2014), CAIX controls an intracellular
and extracellular acid-base balance that regulates both survival
and invasive properties (Figure 1). The HCO−3 produced by
CAIX re-enters the cell through bicarbonate transporters and
anion exchangers, thereby buffering intracellular acidosis and
facilitating tumor cell survival and growth. The H+ participate
in the generation of an increasingly acidic extracellular
environment, a phenomenon recently demonstrated in models
of colorectal cancer in vivo using hyperpolarized 13C-magnetic
resonance spectroscopy (Gallagher et al., 2015), fueling the
breakdown of the extracellular matrix and facilitating tumor
cell invasion and metastasis (Swietach et al., 2010; McDonald
et al., 2012; Parks et al., 2013; Sedlakova et al., 2014). Congruent
with its role in regulating pH, several studies have demonstrated
that perturbing CAIX function in hypoxia elicits biological
consequences that impede cancer progression and demonstrate
its utility as a therapeutic target.
Stable depletion of CAIX expression or inhibition of its
activity with small molecule inhibitors (discussed in detail below)
in the context of hypoxia results in the inhibition of tumor
growth across multiple models, including breast cancer (Lou
et al., 2011), colorectal cancer (Chiche et al., 2009; McIntyre
et al., 2012) and glioblastoma (McIntyre et al., 2012), and
demonstrates a critical role for CAIX in cancer cell survival
in vivo. Perturbation of CAIX function in hypoxia also blunts
migration and invasion of cancer cells in vitro (Proescholdt
et al., 2012; Lock et al., 2013), and inhibits the formation
of metastases in vivo (Lou et al., 2011; Gieling et al., 2012).
Importantly, the role of CAIX in migration, invasion and
metastasis is linked to its catalytic activity and the production
of H+, which helps to drive development of acidosis within
the extracellular environment and facilitates local invasion
through disruption of the extracellular matrix, activation of
metalloproteases and increased cell invasiveness (Estrella et al.,
2013; Svastova and Pastorekova, 2013; Sedlakova et al., 2014;
Pastorek and Pastorekova, 2015). Furthermore, evidence now
strongly suggests that CAIX is an integral functional component
of CSCs. Several studies have shown that CAIX is required
for stemness properties of CSCs in hypoxia (Lock et al., 2013;
Papi et al., 2013; Ledaki et al., 2015; Pore et al., 2015),
and treatment of orthotopic human breast cancer xenografts
with specific small molecule inhibitors of CAIX significantly
reduced the CSC population. Increased CAIX expression was also
observed in the tumor initiating cell fraction of pancreatic ductal
adenocarcinoma in a patient-derived xenograft cell line and
targeting CAIX expression in this population of cells with shRNA
greatly reduced their tumor initiating capacity (Pore et al., 2015).
Together, these studies demonstrate a functional role of CAIX
in maintenance of the CSC population in vivo and suggest that
pharmacologic targeting of CAIX may be effective at reducing or
eliminating CSCs in hypoxia, a cell population that is resistant to
conventional chemotherapy and radiotherapy. These attributes,
together with its ease of accessibility to pharmacologic agents
due to its membrane-bound, extracellular catalytic domain, have
made CAIX a very attractive target for cancer therapy (Neri and
Supuran, 2011; Wilson and Hay, 2011; McDonald et al., 2012;
Supuran, 2012; Pastorek and Pastorekova, 2015).
It is clear from the discussion above that therapeutic
targeting of CAIX holds potential for enhanced treatment efficacy
through the elimination of aggressive cancer cells that have
adapted to hypoxia, a realization that has spawned extensive
efforts to develop therapeutics targeting CAIX. Two overarching
and complementary approaches have been utilized to target
CAIX for cancer treatment. One approach has involved the
development of therapeutic modalities, especially CAIX-specific
small molecule inhibitors that directly target the catalytic activity
of CAIX, thereby exploiting the biological roles of CAIX,
including pH regulation, migration and invasion, and CSC
maintenance (Figure 1). A second, complementary approach
exploits the tumor-specific upregulation of CAIX as a highly
selective “address” to which to deliver CAIX-specific monoclonal
antibodies, either alone or in combination with cytotoxic or
radioactive warheads to elicit killing of hypoxic tumor cells. Both
of these approaches are discussed below.
Small Molecule Inhibitors
The development of small molecule inhibitors of CA activity
that are selective for cancer associated extracellular CAs such
as CAIX (and CAXII) over other, closely related “off-target”
CA isoforms has been an area of intense investigation during
the past few years (Neri and Supuran, 2011; Supuran, 2012).
These studies have resulted in a large number of novel, potent
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FIGURE 1 | Combinatorial approaches to target the hypoxic TME and anti-angiogenic resistance. Hypoxia induces a HIF-1-mediated signaling cascade that
results in nuclear translocation of HIF-1α and activation of hypoxia-regulated genes, including GLUT1, MCT4, and CAIX. The decreased oxygen availability forces
tumor cells to become reliant upon glycolysis for energy production, the “glycolytic switch”; the concomitant accumulation of intracellular glycolytic byproducts forces
the upregulation of transporters, MCT1/4, to cope with the declining pHi, thus acidifying the extracellular environment. The upregulation of CAIX contributes to the
decreasing pHe, through the production of H+, and to the regulation of pHi through the production of HCO−3 , which re-enters the cell and buffers intracellular
acidosis. The declining pHe activates proteases, increasing migration and invasion and reduces immune function. The use of anti-angiogenic drugs, tyrosine kinase
inhibitors or VEGF antibodies (Bevacizumab and TKI’s), increases the hypoxic fraction of the tumor and engages the HIF program. This adaptation may then render
those cancer cells vulnerable to the metabolic adaptations initiated above. Blocking the pH regulatory machinery, CAIX and MCTs, may be an effective combinatorial
strategy for reducing tumor cell survival and overcoming resistance to anti-angiogenic therapy. Stromal cell populations (MDSC, TAM, and Treg) recruited to the
hypoxic niches of solid tumors contribute to resistance to anti-angiogenic therapy. Limiting their recruitment to the TME by reducing circulating levels of soluble factors
(e.g., G-CSF, CCL28) or antagonizing cellular receptors (PLX3397) needed for their chemotaxis in combination with the modalities mentioned above may reduce
resistance to anti-angiogenic therapy and improve therapeutic outcome. pHe, extracellular pH; pHi, intracellular pH; mAb, monoclonal antibody; CAI, carbonic
anhydrase inhibitor; HCO−3 , bicarbonate; H
+, proton; CO2, carbon dioxide; H2O, water; NBC, sodium/bicarbonate cotransporter; MCT1/4, monocarboxylate
transporter 1 and 4; HIF-1α, hypoxia-inducible factor 1 alpha; ARNT, aryl hydrocarbon receptor nuclear translocator; LDH, lactate dehydrogenase; OXPHOS, oxidative
phosphorylation; CAII, carbonic anhydrase II; CAIX, carbonic anhydrase IX; GLUT-1, glucose transporter 1; Sema3A, semaphorin 3A; VEGF, vascular endothelial
growth factor; CCL28, chemokine (C-C motif) ligand 28; CCR10, chemokine (C-C motif) receptor 10; Arg1, arginase 1; iNOS, inducible nitric oxide synthase; CSF1R,
colony stimulating factor 1 receptor; TCR, T cell receptor; G-CSF, granulocyte colony stimulating factor; TAM, tumor associated macrophage; MDSC, myeloid-derived
suppressor cell; Treg, regulatory T cell; ECM, extracellular matrix; MMP9, matrix metalloprotease 9; VEGFR1, vascular endothelial growth factor receptor 1; VEGFR2,
vascular endothelial growth factor receptor 2; TKI, tyrosine kinase inhibitor.
CAIX-selective inhibitory compounds, some of which are now
being evaluated in vivo and in the clinic (McDonald et al., 2012;
McDonald and Dedhar, 2014). While initial strategies to enhance
CAIX selectivity of the pan CA inhibitor, acetazolamide, were
met with limited success (Ahlskog et al., 2009; Chiche et al.,
2009), a series of novel, potent, CAIX-selective “next generation”
small molecule inhibitors are showing great promise. Several
classes of novel CAIX inhibitors, including ureidosulfonamides
(Pacchiano et al., 2011), glycosyl coumarins (Touisni et al., 2011)
and indanesulfonamides (Dubois et al., 2011) have been used
successfully to inhibit tumor growth in preclinical models of
hypoxic, CAIX-positive breast cancer (Lou et al., 2011; Pacchiano
et al., 2011; Touisni et al., 2011) and colorectal cancer (Dubois
et al., 2011), demonstrating that the selective pharmacologic
inhibition of CAIX activity elicits an anti-tumor effect in vivo.
Furthermore, the ureidosulfonamide and glycosyl coumarin
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TABLE 1 | Clinical trials targeting pH regulators in cancer.
Target Drug Intervention Phase Identifier
CAIX SLC-0111 Advanced solid tumors 1 NCT02215850
CAIX Girentuximab
(cG250)
Kidney Cancer 3 NCT00087022
CAIX DTP-348 Solid tumors 1 NCT02216669
CAIX 177Lu-cG250 Metastatic RCC 2 NCT00142415
CAIX AdGMCAIX
transduced DC
Metastatic RCC 1 NCT01826877
MCT1 AZD3965 Solid tumors, Gastric
and prostate cancer,
DLBCL
1 NCT01791595
DC, dendritic cell; RCC, renal cell carcinoma; DLBCL, diffuse large B cell lymphoma.
inhibitors were effective in reducing lung metastases (Lou et al.,
2011; Pacchiano et al., 2011), as was a sulfamate inhibitor of CAIX
(Gieling et al., 2012), and in depleting CSCs in models of breast
cancer metastasis (Lock et al., 2013), showing the value of CAIX
inhibitors as therapeutic agents for use in targeting metastasis
and chemoresistant tumor initiating cells.
These exciting data and further assessment of lead compounds
resulted in the selection of a novel, first in class, highly selective
ureidosulfonamide inhibitor of CAIX and CAXII, SLC-0111
(aka U-104; Lou et al., 2011; Pacchiano et al., 2011), for
clinical development. Pharmacokinetic and toxicology studies
demonstrated negligible toxicity and>10-fold therapeutic index,
and SLC-0111 is orally bioavailable. SLC-0111 is now the
subject of a first in man, multi-center phase 1 clinical trial
(NCT02215850) in patients with solid tumors and is nearing
completion of recruitment (Table 1). In addition to this pivotal
clinical trial, data demonstrating preclinical efficacy of another
CAIX inhibitor/radiosensitizer, DTP-348, in breast and colorectal
models alone and in combination with either ionizing radiation
(Dubois et al., 2013; Ward et al., 2015) or doxorubicin (Rami
et al., 2013) has resulted in reports of a phase 1 clinical trial
(NCT02216669) in patients with solid tumors (McIntyre and
Harris, 2015; Table 1). However, this study is not currently open
for recruitment of patients. Importantly, if clinical trials utilizing
inhibitors of CAIX activity are to be successful, selection of those
patients likely to respond to therapy is critical. Only patients
whose tumors require CAIX function for survival, growth and
metastasis are likely to benefit. Thus, predictive biomarkers,
including CAIX expression and additional measures of hypoxia
response, will be necessary to guide patient selection for these
therapies.
Therapeutic Antibodies against CAIX
Immunotherapy using CAIX-specific monoclonal antibodies
(mAbs) may derive its therapeutic efficacy through several
mechanisms (McDonald et al., 2012; Pastorek and Pastorekova,
2015) (Figure 1). For example, direct binding of the mAb
to CAIX can elicit an anti-tumor response due to antibody-
mediated cell cytotoxicity (ADCC). Alternatively, high affinity
CAIX mAbs capable of receptor-mediated internalization have
the potential to provide effective vehicles for targeted delivery
of various therapeutic compounds, including cytotoxins and
radionuclides, as has been demonstrated clinically for antibody-
drug conjugates such as ado-trastuzumab emtansine (T-DM1) in
breast cancer (Lambert and Chari, 2014).Thus, the development
of CAIX-specific therapeutic mAbs is an active area of research
and one with potential to yield important advances in cancer
therapy.
Girentuximab (cG250) is arguably the most clinically
advanced mAb against CAIX, particularly for renal cell
carcinoma (Oosterwijk, 2008; Oosterwijk-Wakka et al., 2013).
Initial studies demonstrated that cG250 could elicit antibody-
dependent cellular cytotoxicity (ADCC) (Surfus et al., 1996), an
established mechanism by which therapeutic mAbs function to
destroy tumor cells. This property of therapeutic mAbs is well-
established clinically, and a recent study has demonstrated that
modification of the Fc region of a CAIXmAb originally identified
in a high throughput screen (Xu et al., 2010) increased ADCC
in vitro and was effective at targeting orthotopic RCC tumors
in an immunocompromised mouse model following allogeneic
transplantation of human peripheral blood mononuclear cells
(Chang et al., 2015). Girentuximab is marketed by WILEX AG
under the trade name RENCAREX R© and Phase I and II trials
demonstrated that this Ab was safe, well-tolerated and able to
positively impact disease burden, alone and together with IL-2
treatment (Davis et al., 2007; Zatovicova et al., 2010; Neri and
Supuran, 2011; Siebels et al., 2011). However, a phase 3 trial
(ARISER; NCT00087022) targeting patients with non-metastatic
renal cell carcinoma failed to show an improvement in disease-
free survival with treatment (Pastorek and Pastorekova, 2015). It
should be noted that this study lacked stratification of patients
based on CAIX expression which, if accounted for, showed
significant improvement in the subset of patients with high CAIX
expression, demonstrating the need for guided patient selection
for CAIX-based therapies.
In addition to direct stimulation of the host immune response,
mAbs may be used as a target-specific vehicle for the delivery
of therapeutic payloads (Scott et al., 2012). Internalization of
mAbs is required for delivery of radioisotopes and cytotoxic
drugs to cancer cells, and CAIX mAbs have been developed
that exploit this functionality. For example, the cG250 mAb
can be internalized by cancer cells (Zatovicova et al., 2014),
and treatment of xenograft tumors with radioimmunoconjugates
employing the cG250 mAb has demonstrated a delay in growth
(Brouwers et al., 2004). Recently, a phase II trial in patients
with metastatic clear cell renal carcinoma (mccRCC) treated
with 177Lu-Girentuximab achieved stable disease in 9 of 14
patients (Muselaers et al., 2015; Table 1), demonstrating the
potential utility of such conjugates in CAIX-positive disease.
Furthermore, a study in which a novel CAIX mAb was
conjugated to the microtubule inhibitor monomethyl auristatin
E (MMAE) (BAY79-4620) demonstrated efficacy in several
preclinical human xenograft tumor models in which the level
of efficacy correlated with the level of CAIX expression (Petrul
et al., 2011). A phase 1 clinical trial (NCT01028755) involving
the treatment of patients with solid tumors with BAY79-4620
was initiated, but was terminated early due to issues related to
patient safety. While the basis for the adverse safety profile of this
ADC is not known, recent improvements in ADC technology,
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including the use of non-cleavable linkers, will certainly provide
avenues for continued development of ADCs using CAIX as a
target.
In addition to small molecule inhibitors and antibodies, other
modalities for targeting CAIX in vivo are showing promise.
For example, small molecule drug conjugates comprised of
an acetazolamide derivative linked to the maytansinoid DM1
were found to accumulate in CAIX-positive lesions and have
antitumor effects using the SKRC52 renal cell carcinoma model
(Krall et al., 2014). Such conjugates have the advantage of
increased access to tumor tissue while enabling delivery of
potent cytotoxic compounds (Wichert and Krall, 2015) and
engineering of conjugates using current, highly CAIX-specific
small molecules may prove effective. Interestingly, a dendritic cell
(DC) based vaccine designed to use CAIX as a tumor associated
antigen for immune targeting where DCs are engineered to
express the GM-CSF-CAIX (AdGMCAIX) fusion protein has
been developed. This vaccine has demonstrated preclinical
success in a model of RCC when treated in an immunization or
intervention setting (Birkhäuser et al., 2013). Based on the recent
FDA approval of the DC based vaccine Sipuleucel-T and with
other vaccines in phase III evaluation (Palucka and Banchereau,
2013), it will be interesting to see how the AdGMCAIX vaccine
progresses clinically as a trial has been initiated (Table 1) and
is recruiting patients to test this vaccine in metastatic RCC
(NCT01826877). Together, these therapeutic strategies provide
a robust platform for targeted treatment of hypoxic tumors in
patients.
MCT1 and MCT4
Cancer cells relying on glycolysis to support survival and
rapid proliferation in hypoxia produce large amounts of acidic
byproducts, particularly lactate (Gatenby and Gillies, 2008;
Gillies et al., 2012; Marchiq and Pouysségur, 2015; Parks et al.,
2015). The production of lactate contributes to intracellular
acidosis, a situation requiring an adaptive response to increase
lactate eﬄux and potentiate survival (Parks et al., 2015). Cancer
cells enhance the eﬄux of lactate through the upregulation
of members of the MCT family of lactate/H+ symporters
(Doherty and Cleveland, 2013). Two members of this family,
MCT1 and MCT4, are upregulated in several cancers, including
breast, colorectal, lung, kidney, and glioblastoma (Doherty and
Cleveland, 2013; Doyen et al., 2014), and function to regulate
lactate transport across the plasma membrane (Halestrap, 2013;
Marchiq and Pouysségur, 2015). The differential distribution of
MCT1 and MCT4 in cancer cells highlights their distinct roles
in lactate transport and demonstrates cooperativity between the
two transporters. MCT4 is upregulated in hypoxia as a direct
target of HIF-1α and functions to export lactate from hypoxic
tumor cells (Doherty and Cleveland, 2013; Parks et al., 2015).
Importantly, MCT-mediated extrusion of lactate contributes to
acidosis of the TME and plays a role in tumor cell migration
and invasion, angiogenesis and immunosuppression (Marchiq
and Pouysségur, 2015; Figure 1). MCT1, in contrast, is expressed
on oxidative tumor cells and functions to import lactate to feed
the TCA cycle through conversion to pyruvate, forming a lactate
shuttle and engaging a process termed “metabolic symbiosis”
(Payen et al., 2015b). The reliance of hypoxic tumor cells onMCT
function to adapt to the potentially detrimental consequences
of acidosis and the cooperativity that exists between MCT1 and
MCT4 in regulating lactate levels in hypoxia has opened the door
to targeting both of these transporters for cancer therapy.
Significant efforts are currently underway to target the MCTs
with small molecule inhibitors. While the first generation MCT
inhibitors were not clinically viable, owing to a lack of MCT
specificity and associated toxicity (Marchiq and Pouysségur,
2015), a potent, second generation MCT1 inhibitor from
AstraZeneca, AZD3965, has shown anticancer effects in a
variety of cancer cell lines (Bola et al., 2014; Polanski et al.,
2014) and treatment of tumors in vivo reduced tumor growth
and increased sensitivity to radiation (Bola et al., 2014).
AZD3965 is undergoing phase 1 clinical trials (NCT01791595)
for solid tumors and diffuse large B cell lymphoma (Marchiq
and Pouysségur, 2015; Table 1). There have also been efforts
to target CD147/Basigin, a transmembrane glycoprotein that
functions as a chaperone for folding and trafficking of MCT1
and MCT4 to the plasma membrane (Doherty and Cleveland,
2013; Marchiq and Pouysségur, 2015). Genetic depletion of
CD147, when coupled to MCT1 and MCT4, reduced the
growth of colon carcinoma tumors (Le Floch et al., 2011).
Directed targeting of CD147 has focused on antibody-based
therapeutics and mAbs against CD147 have shown efficacy
in preclinical cancer models. However, studies have shown
that functional redundancy exists between MCT1 and MCT4,
and genetic silencing or pharmacological inhibition of MCT1
in human colon adenocarcinoma cells was effective only
when combined with MCT4 depletion (Le Floch et al.,
2011; Marchiq and Pouysségur, 2015). These results suggest
that combinatorial targeting of MCT1 and MCT4 may be
required to elicit a robust therapeutic response. It has also
been suggested that a limitation of targeting MCTs may be
the potential for on-target toxicity in normal tissues and
dose limiting side effects in humans due to their ubiquitous
expression and involvement in multiple functions, including
metabolism, pH regulation, angiogenesis and the immune
response (Marchiq and Pouysségur, 2015). However, despite
these potential challenges, emerging data demonstrates the
potential power of targeting MCT4, particularly for hard-to-treat
cancers.
Upregulated MCT4 expression has been reported in human
breast cancer, with especially high levels in aggressive, triple
negative breast cancer cells that correlated with decreased
overall survival (Doyen et al., 2014). MCT4 was also found
to be a key regulator of breast cancer cell metabolism and
survival in an unbiased, functional RNAi screen and silencing
its expression reduced glycolytic flux, increased dependence
on oxidative phosphorylation and glutamine metabolism, and
reduced spheroid growth (Baenke et al., 2015). It has also been
shown recently that MCT4 is over-expressed in a glycolytic
subtype of pancreatic cancer and its depletion in xenograft
models significantly impacted tumor metabolism and rapid
tumor growth (Baek et al., 2014). To date, inhibitors specific
for MCT4 have not become available, although one report has
suggested that AstraZeneca is currently testing a potent, specific
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MCT4 inhibitor (Marchiq and Pouysségur, 2015). It remains to
be seen whether co-targeting of MCT1 and MCT4 in the context
of hypoxia will provide therapeutic benefit. However, together
with CAIX, MCT4 plays an important role in the maintenance
of glycolytic flux and pH regulation in hypoxic tumor cells and
suggests that cotargeting of MCTs and CAIXmay serve to further
limit the growth of hypoxic solid tumors.
TARGETING ANGIOGENESIS
Inhibition of vascularization by treatment with inhibitors of
angiogenesis, generally termed anti-angiogenic agents, thereby
effectively starving tumor cells of nutrients and oxygen, is a
clinically validated strategy for cancer therapy (De Bock et al.,
2011; Jain, 2014). However, what was seen initially as a panacea
for cancer patients has fallen short of expectations. In particular,
many patients fail to respond to anti-angiogenic therapy and
those who do often show only a modest survival benefit
(Rapisarda and Melillo, 2012; McIntyre and Harris, 2015). While
vascular “normalization” can occur and leads to reduced hypoxia
and interstitial pressure in the TME, thereby increasing perfusion
and improving delivery of chemotherapeutic agents (Jain, 2014;
McIntyre and Harris, 2015), the most frequent response to anti-
angiogenic therapy is vascular regression and vessel pruning,
resulting in increased intratumoral hypoxia (Rapisarda and
Melillo, 2012; McIntyre and Harris, 2015), as assessed by hypoxic
gene signatures and increased expression of hypoxia-induced
effectors, including CAIX.
Many patients are innately resistant to anti-angiogenic agents
or rapidly develop acquired resistance in response to treatment.
Amongst several resistance mechanisms that have been identified
to enable cancer cells to circumvent angiogenesis blockade (van
Beijnum et al., 2015), the development of increased intratumoral
hypoxia as a result of extensive vessel pruning is of critical
importance (Rapisarda et al., 2009; Hu et al., 2012;McIntyre et al.,
2012; Rapisarda and Melillo, 2012; Kim et al., 2013; McIntyre
and Harris, 2015). Treatment with anti-angiogenic agents has
resulted in increased invasiveness and consequently metastases
preclinically (Ebos et al., 2009; Pàez-Ribes et al., 2009). However,
at least one retrospective study suggests that this is not the
case in the clinical setting, although the patients investigated
often had metastatic disease at the time of treatment initiation
(Miles et al., 2011). In addition, it was recently demonstrated
that this difference between the preclinical and clinical realms
was likely the result of patients being treated with chemotherapy
in combination with anti-angiogenic agents, as this combination
tested preclinically eliminated the increased metastasis observed
from treatment with anti-angiogenic agents alone (Paez-Ribes
et al., 2015).
Since the hypoxia induced by anti-angiogenic therapy
stimulates adaptations by the tumor cells that promote
therapeutic resistance, it has been suggested that these
adaptations may now be critical for survival, producing
a type of synthetic lethality termed “induced essentiality”
(McIntyre and Harris, 2015). Targeting critical downstream
effectors of hypoxia, or HIF-1α itself, has provided a therapeutic
advantage in preclinical models (Rapisarda et al., 2009; Hu et al.,
2012; McIntyre et al., 2012; Kim et al., 2013). Furthermore, as
a consequence of treatment induced hypoxia, CAIX expression
is significantly upregulated, suggesting that targeting CAIX
in combination with anti-angiogenic agents may provide an
effective therapeutic strategy (Hu et al., 2012; Kim et al., 2013).
McIntyre and colleagues provided proof of principle data for
this co-targeting strategy by showing that genetic depletion
of CAIX in combination with bevacizumab in models of
colorectal cancer and glioblastoma resulted in a significant
delay in tumor growth (McIntyre et al., 2012). Similar results
were observed upon treatment with the broad spectrum
carbonic anhydrase inhibitor, acetazolamide. Acetazolamide
was also utilized recently in combination with bevacizumab
in a model of cholangiocarcinoma. While bevacizumab alone
showed considerable efficacy in this model, the combination
of bevacizumab with acetazolamide further delayed tumor
growth (Vaeteewoottacharn et al., 2016). However, the lack of
specificity of acetazolamide is a significant caveat of these studies,
and investigation of therapeutic combinations using inhibitors
specific for CAIX, such as SLC-0111, should be undertaken. In
addition to VEGF antibodies, tyrosine kinase inhibitors have
been utilized to block angiogenic signaling at the level of the
cellular receptors. Treatment of patients with metastatic clear cell
renal cell carcinoma with sunitinib results in objective response
rates of 40% (Molina et al., 2014). Combinatorial treatment with
the CAIX antibody, cG250/Girentuximab, in combination with
sunitinib was tested clinically in patients with metastatic RCC
(NCT00520533). Unfortunately, the trial ended early due to
toxicity issues. Based on preclinical studies, it is clear that this is
an area that warrants careful evaluation clinically with rational
therapeutic combinations targeting treatment induced hypoxia.
The hypoxic niche of solid tumors is an environment
that drives aggressive tumor cell behavior and is a known
source of cancer stem cells (CSCs; Currie et al., 2013). As
conventional chemotherapy and radiation treatment are known
to be less effective in this microenvironment, rational drug
combinations need to be developed in order to effectively
overcome treatment failure due to therapy induced adaptations.
Interestingly, sunitinib and bevacizumab treatment of breast
cancer xenografts was demonstrated to increase intratumoral
hypoxia and the population of stem cells found within the
tumor (Conley et al., 2012). Therefore, it is conceivable that
combining drugs that increase intratumoral hypoxia with a drug
that can effectively eradicate the CSC pool in the hypoxic niche,
such as CAIX inhibitors, may overcome treatment resistance.
Alternatively, therapeutic initiatives aimed at promoting re-
oxygenation of tumor tissues, including vessel normalization
strategies (Jain, 2014) and the use mild hyperthermia (Moon
et al., 2010; Datta et al., 2015) in combination with radiotherapy
or chemotherapy are proving successful in the clinic. Recent
technological advances in the delivery of hyperthermia as a
radio- and chemosensitizer, together with the relative absence
of additional significant toxicity, have reinvigorated efforts using
thermoradiotherapy and thermochemotherapy (Moon et al.,
2010; Datta et al., 2015) as combinatorial treatment strategies for
hypoxic, solid tumors.
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TARGETING IMMUNE DYSFUNCTION
The cellular composition of solid tumors consists of many
stromal cell types in addition to the epithelial cancer
cells (Gabrilovich et al., 2012). There exists an extensive
communication network between the stroma and the tumor
that ultimately results in the hijacking of the stroma by the
tumor supporting disease progression, increased invasiveness
and enhanced metastatic propensity, angiogenesis, therapeutic
resistance and resistance to immune cell eradication mechanisms
(Gabrilovich et al., 2012; Quail and Joyce, 2013). The
contribution of the various stromal cell types to the tumor
have been reviewed extensively elsewhere (Hanahan and
Coussens, 2012; Junttila and de Sauvage, 2013). Here, we will
focus on three very prominent stromal cell types that mediate
immunosuppression in the hypoxic TME and allow the tumor
to escape immune detection: myeloid-derived suppressor
cells (MDSC), regulatory T cells (Treg) and tumor associated
macrophages (TAMs). We will discuss the various mechanisms
by which these cell types contribute to tumor progression
and therapeutic resistance in the context of hypoxia, as well
as the efforts to target the immunosuppressive functions of
these cell populations, especially using immune checkpoint
inhibitors.
Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSC) are an
immature myeloid cell population named for their potent
immunosuppressive ability toward T and NK cells (Bronte, 2009;
Gabrilovich and Nagaraj, 2009) which play a prominent role in
tumor progression (Talmadge and Gabrilovich, 2013). In healthy
individuals this population is present in very small numbers
in the bone marrow, lacks immunosuppressive activity and
readily differentiates into mature macrophages and neutrophils.
However, in mice and patients with cancer this differentiation is
diverted by the abnormally high levels of tumor-derived myeloid
growth factors in the blood (Messmer et al., 2015) and circulating
MDSC levels have been shown to correlate with increased disease
burden in patients with cancer (Diaz-Montero et al., 2009;
Messmer et al., 2015). Recruitment of MDSC to tumors has been
shown to occur in response to multiple soluble factors, although
the precise chemotactic factors involved vary depending on the
tumor model interrogated (Acharyya et al., 2012; Gabrilovich
et al., 2012; Wesolowski et al., 2013; Highfill et al., 2014; Palazon
et al., 2014). Together with these soluble factors, tumor hypoxia,
via HIF-1α stabilization and the production of downstream
effectors, plays a role in facilitating MDSC mobilization into
the circulation and recruitment to tumors (Du et al., 2008;
Erler et al., 2009; Wong et al., 2011; Sceneay et al., 2012; Chafe
et al., 2015; Figure 2), and regulates the immunosuppressive
functions of MDSC (Corzo et al., 2010). Recently, hypoxia
was further implicated in expanding the immunosuppressive
arsenal of MDSC through the HIF-1 mediated upregulation
of programmed cell death 1 ligand 1 (PD-L1; Noman et al.,
2014). Moreover, the response to hypoxia has been shown to
impact MDSC by triggering rapid differentiation into TAM
(Corzo et al., 2010). The same study also identified increased
F4/80 (macrophages) positivity relative to Gr1 (MDSC) in
hypoxic, pimonidazole staining regions of tumors, suggesting
that TAM arising from MDSC may be vitally important for
tumor progression in these niches.
MDSC suppress the anti-tumor immune response
(Gabrilovich et al., 2012), therapeutic efforts to restore this
response (Highfill et al., 2014; Kim et al., 2014), as well as
limit the efficacy of anti-angiogenic (Shojaei et al., 2007, 2009)
and chemotherapies (Acharyya et al., 2012). Consequently, a
number of therapeutic approaches to target MDSC are being
explored which can be grouped into 4 distinct categories: (1)
forced differentiation (2) targeting soluble factors mediating
expansion and/or recruitment (3) direct targeting with the use of
chemotherapy (4) reducing their immunosuppressive capacity.
Each of these therapeutic strategies has been reviewed extensively
in Wesolowski et al. (2013) and targeting MDSCs using immune
checkpoint inhibitors is discussed below.
Regulatory T Cells
Regulatory T cells (Treg) are another important stromal cell
population that supports tumor progression by contributing
to immune evasion (Facciabene et al., 2012). Similar to
MDSC, Treg are normally required to keep the immune
system tightly regulated and prevent autoimmunity. Treg are
found in one of two forms: natural Treg (nTreg) which are
thymically derived, or induced Treg (iTreg) which can be
induced from naïve CD4 T cells. The fate and function of
these populations are controlled by the expression of the
FoxP3 transcription factor (Facciabene et al., 2012). Treg
have been identified in many cancers where they have been
associated with worse prognosis (Zou, 2006; Facciabene et al.,
2012).
Like MDSC, Treg have a number of weapons to reduce anti-
tumor immunity such as the secretion of immunosuppressive
cytokines, direct killing of effector cells, increasing local pools
of the toxic metabolite adenosine and disruption of dendritic
cell function (Facciabene et al., 2012). Hypoxia-induced CCL28
secretion by the tumor has been shown to induce the
CCR-10-dependent recruitment of Treg to tumors (Figure 2),
exacerbating the immunosuppressive pressure that allows the
tumor to evade host destruction (Schlecker et al., 2012). It has
also been shown that Treg are important for the formation of new
blood vessels in the tumor (Facciabene et al., 2011). Importantly,
these cells can be targeted by immune checkpoint inhibitors such
as ipilimumab (anti-CTLA-4; Selby et al., 2013).
Tumor Associated Macrophages (TAM)
Tumor-associated macrophages make up the largest population
of stromal cells within growing solid tumors and while they
are generally described as belonging to the classically activated
M1 or the alternatively activated M2 phenotype, these cells
actually display a great degree of phenotypic plasticity (Noy
and Pollard, 2014). The M1 phenotype is tumoricidal and
pro-inflammatory, whereas the M2 phenotype is pro-tumoral
and suppresses the inflammatory response (Noy and Pollard,
2014). The recruitment of macrophages to tumors is largely
dependent upon soluble factors released into the circulation
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FIGURE 2 | Combinatorial approaches to target the hypoxic TME and immune dysfunction. In addition to the metabolic adaptations initiated by engagement
of the HIF program in the hypoxic niches of the tumor contributing to the migratory and invasive phenotype of the cancer cells, metabolic byproducts (e.g., low pH)
reduce anti-tumor immune function. Furthermore, many HIF target genes (e.g., VEGF, Sema3A, CCL28) secreted by the tumor result in chemotaxis of immune
suppressive cell populations (MDSC, TAM, and Treg), limiting the function of anti-tumor immune response. In addition HIF-1-mediated upregulation of PD-L1 by the
tumor, MDSC and TAM populations provides an additional layer of resistance to immune surveillance mechanisms. Consequently the use of checkpoint inhibitors to
restore anti-tumor immunity to eradicate the therapy resistant cells in the hypoxic TME in combination with inhibitors of pH regulation and recruitment of immune
suppressive stromal cell populations may circumvent many of the hurdles facing anti-tumor immunity. pHe, extracellular pH; pHi, intracellular pH; mAb, monoclonal
antibody; CAI, carbonic anhydrase inhibitor; HCO−3 , bicarbonate; H
+, proton; CO2, carbon dioxide; H2O, water; NBC, sodium/bicarbonate cotransporter; MCT1/4,
monocarboxylate transporter 1 and 4; HIF-1α, hypoxia-inducible factor 1 alpha; ARNT, aryl hydrocarbon receptor nuclear translocator; LDH, lactate dehydrogenase;
OXPHOS, oxidative phosphorylation; CAII, carbonic anhydrase II; CAIX, carbonic anhydrase IX; GLUT-1, glucose transporter 1; Sema3A, semaphorin 3A; VEGF,
vascular endothelial growth factor; CCL28, chemokine (C-C motif) ligand 28; CCR10, chemokine (C-C motif) receptor 10; Arg1, arginase 1; iNOS, inducible nitric
oxide synthase; CSF1R, colony stimulating factor 1 receptor; TCR, T cell receptor; G-CSF, granulocyte colony stimulating factor; TAM, tumor associated macrophage;
MDSC, myeloid-derived suppressor cell; Treg, regulatory T cell; APC, antigen presenting cell; VEGFR1, vascular endothelial growth factor receptor 1; VEGFR2,
vascular endothelial growth factor receptor 2; CTLA-4, cytotoxic T lymphocyte antigen-4; PD-1, programmed cell death receptor 1; PD-L1, programmed cell death 1
ligand.
by the tumor, including CCL2, CCL5, VEGF, Endothelins,
endothelial monocyte activating polypeptide (EMAP) II and
colony stimulating factor 1 (CSF1), resulting in the mobilization
of monocytes from the bone marrow (Murdoch et al., 2004;
Franklin et al., 2014). Once macrophages reach the tumor,
migration to the hypoxic regions is driven by VEGF, EMAPII,
Endothelin-2, CXCR4 and Semaphorin3A (Murdoch et al., 2004;
Casazza et al., 2013; Figure 2). While tumor hypoxia was thought
to play a prominent role in polarizing TAMs, recent findings
suggest that tumor hypoxia merely enhances the expression of
pro-angiogenic and metastasis promoting genes (Laoui et al.,
2014). TAMs expressing M2 markers were found in the same
proportion in well oxygenated and poorly oxygenated tumors
in a model of PHD2 haploinsufficiency (Laoui et al., 2014).
However, immunosuppressive M2 macrophages are found in
greater number in hypoxic regions of solid tumors compared to
M1 macrophages (Murdoch et al., 2004; Movahedi et al., 2010;
Laoui et al., 2014), supporting a role for hypoxia in M2 TAM
chemotaxis and retention in these niches. Hypoxic TAMs provide
a rich source of VEGF, augmenting tumor angiogenesis, blood
vessel dysfunction and exacerbation of the hypoxia (Stockmann
et al., 2008; Figure 2). VEGF secreted by macrophages is also
responsible for a role of macrophages in assisting the transit
of migratory tumor cells into the vasculature to facilitate their
entrance into the circulation (Harney et al., 2015). These
macrophages, together with the migratory cancer cells and
the endothelial cells, form the “tumor microenvironment of
metastasis” (TMEM). The TMEM has been observed in the
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tumors of breast cancer patients where it has been shown to be
predictive of metastatic potential in ER+HER2− cases (Rohan
et al., 2014).
The highly immunosuppressive nature of macrophages poses
a significant hurdle to anti-tumor immunity especially in hypoxic
regions of tumors and TAM presence has been shown to
impact breast cancer patient survival (Doedens et al., 2010;
DeNardo et al., 2011; Casazza et al., 2013). The stabilization
of HIF-1α is required for the immunosuppressive activity of
macrophages by increasing the expression of Arg1 and iNos
activity (Doedens et al., 2010). Therefore, eliminating this
immunosuppressive population is critical for restoring anti-
tumor immunity. Recently it was shown that blocking the
recruitment of macrophages using antibody blockade of CSF1 or
CSF1R antagonism with the small molecule inhibitor PLX3397,
which is being evaluated clinically, resulted in a CD8 T cell
dependent reduction in tumor burden in the MMTV-PyMT
model (DeNardo et al., 2011). As hypoxia has also been
shown to upregulate PD-L1 expression on TAMs, treatment
of tumors with high TAM presence with immune checkpoint
inhibitors may also restore anti-tumor immunity (Noman et al.,
2014).
Targeting the Immune Response with
Checkpoint Inhibitors
Recent clinical breakthroughs in targeting tumor immunology
through the use of immune checkpoint inhibitors have revitalized
interest in the field (Hodi et al., 2010; Brahmer et al., 2012;
Topalian et al., 2012; Wolchok et al., 2013). However, despite the
significant measurable responses observed clinically, treatment
with inhibitors to PD-1 and CTLA-4 have only produced
objective responses in 10–28% of patients treated when utilized
as a monotherapy (Hodi et al., 2010; Brahmer et al., 2012;
Topalian et al., 2012). Achieving an understanding of the
mechanisms limiting the response to these antibodies as well as
the identification of biomarkers that can be utilized to stratify
patients that will respond to this therapy alone or may require
a combinatorial approach will improve patient outcome.
In order to achieve activation, a T cell must recognize a
peptide antigen presented by a major histocompatibility complex
(MHC) molecule on the surface of an antigen presenting cell
(APC) or cancer cell via its T cell receptor (TCR). When this is
done in the context of appropriate stimulating signals through
the engagement of costimulatory molecules (e.g., CD28) with
their cognate receptors (e.g., CD80), activation of a T cell occurs
(Pardoll, 2012; Mahoney et al., 2015). Fail safe mechanisms
exist to regulate the activity of the T cell and the duration
of the response through the activity of inhibitory receptors or
checkpoint molecules. As an example, molecules such as PD-
L1 expressed on the surface of APCs or cancer cells binds
to its cognate receptor PD-1. This engagement reduces T cell
activation and cytolytic activity (Pardoll, 2012; Mahoney et al.,
2015; Topalian et al., 2015). Similarly, the expression of cytotoxic
T lymphocyte antigen (CTLA)-4 binds, with higher affinity
than CD28, to CD80 and CD86 on APCs achieving the same
reduction in T cell activation (Pardoll, 2012; Mahoney et al.,
2015; Topalian et al., 2015). This is the basis for immune
checkpoint blockade where antibodies such as ipilimumab (α-
CTLA-4), pembrolizumab (α-PD-1) and nivolumab (α-PD-1)
interfere with the engagement of the inhibitory ligand with the
receptor to maximize anti-tumor immunity (Figure 2). However,
there are significant hurdles to initiating and maintaining this
immune response in various cancers, which include the presence
of a hypoxic, acidic tumor microenvironment (Kareva and
Hahnfeldt, 2013; Motz and Coukos, 2013; Palazon et al., 2014;
Joyce and Fearon, 2015; Wherry and Kurachi, 2015).
Recently it has been shown that hypoxia contributes
to the limited success of an anti-tumor immune response
(Barsoum et al., 2014a). Hypoxia triggers the shedding of
major histocompatibility complex (MHC) class I chain-related
molecule A (MICA), a ligand required for natural killer (NK) cell
and effector cell activation, in an ADAM10 dependent manner,
contributing to the evasion of immune surveillance mechanisms
(Siemens et al., 2008; Barsoum et al., 2011). Furthermore,
hypoxia-induced autophagy was demonstrated to limit NK-
mediated cell death inmodels of breast cancer andmelanoma due
to autophagosome degradation of granzyme B (Baginska et al.,
2013). However, it appears that NK cell mediated tumor killing is
one of several immune surveillance mechanisms in place in the
syngeneic models interrogated as complete tumor regression was
not observed upon autophagy inhibition (Baginska et al., 2013).
Nevertheless, it is clear that cancer cells in low oxygen become
increasingly more difficult for the immune system to eliminate.
It was identified recently that hypoxia, through the action
of HIF-1α, increases the expression of PD-L1 by tumor cells
and by tumor-infiltrating MDSC (Barsoum et al., 2014b; Noman
et al., 2014). In both cases, HIF-1α was found to bind directly
to the hypoxia response element (HRE) in the PD-L1 promoter.
It has been known for a number of years now that cancer
cells within the tumor are capable of expressing PD-L1 in
response to interferon-γ, a significant counter measure to the
activation of T cells (Dong et al., 2002; Curiel et al., 2003; Pardoll,
2012). Barsoum and colleagues demonstrate in vitro that tumor-
educated T cells are much less capable of eliciting a cytolytic
effect on hypoxic cancer cells in a PD-L1 dependent manner
(Barsoum et al., 2014b). However, preclinical studies in multiple
tumor models where antibodies to PD-L1, PD-1 and CTLA-4 are
used as a monotherapy have not achieved much success (Grosso
and Jure-Kunkel, 2013; Highfill et al., 2014; Kim et al., 2014; Guo
et al., 2015; Hu-Lieskovan et al., 2015; Ngiow et al., 2015). Recent
success has been achieved by depleting MDSC in combination
with checkpoint inhibitors (Highfill et al., 2014; Kim et al., 2014).
Depletion through the use of epigenetic modifiers 5-azacytidine
and entinostat, a combination currently being explored clinically
(Kim et al., 2014) (NCT01928576), in models of colorectal and
breast cancer achieved significant anti-tumor effects. A similar
enhancement was observed upon blocking MDSC recruitment
through CXCR2 antagonism in a model of sarcoma (Highfill
et al., 2014). Both studies achieved significant enhancement of
immune checkpoint inhibitor efficacy as a result of removing
multiple layers of immune suppression within the TME. Since
hypoxia is known to recruit MDSC to tumors and induce their
immunosuppressive behavior it is intriguing to explore hypoxia
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driven therapies that may limit the recruitment of MDSC to the
tumor. Indeed, CAIX was shown to be required for mobilization
of MDSC in an implantable model of breast cancer in a G-CSF-
dependent manner facilitating establishment of a breast cancer
pre-metastatic niche (Chafe et al., 2015). Thus, targeting CAIX
in combination with checkpoint inhibitors may prove effective in
this regard.
HYPOXIA-INDEPENDENT MECHANISMS
FOR CAIX INDUCTION
Although hypoxia is arguably the major pathophysiological
stimulus for HIF-1-mediated upregulation of CAIX in solid
tumors, several alternative “provocateurs” present in the TME
may contribute to its induction. For example, it has been
demonstrated that lactate promotes HIF-1α accumulation in
a hypoxia-independent manner in tumor cells through the
inhibition of proline hydroxylation, driving expression of
downstream effectors such as VEGF (Lu et al., 2002; De Saedeleer
et al., 2012), and, potentially, CAIX. The common chemotherapy
drugs paclitaxel, gemcitabine and carboplatin have been recently
shown to induce HIF-1α expression in various models of breast
cancer in a reactive oxygen species dependent manner (Samanta
et al., 2014; Lu et al., 2015). Combination treatments of tumor
xenografts with paclitaxel or gemcitabine in combination with
the HIF-1α inhibitor digoxin proved more effective than either
of the drugs tested as a single agent (Samanta et al., 2014). As the
chemotherapy induced expression of HIF-1α, and downstream
targets, increased the tumorsphere forming capacity of the basal
breast cancer lines tested, it is conceivable that chemotherapy
induced HIF-1α stabilization and a concomitant increase in the
CSC population is a contributing factor to treatment resistance in
vivo. However, randomized clinical trials are needed to confirm
these preclinical findings. In line with these findings, we have
demonstrated in both human and murine breast cancer models
that the combination of paclitaxel with the small molecule
CAIX inhibitor SLC-0111 significantly delayed tumor growth
over either single agent (Lock et al., 2013). Based on the data
presented by Samanta et al. (2014) and Lu et al. (2015), our
observations may be related to increased CAIX expression in
the tumor models tested in response to the chemotherapy
induced initiation of the HIF program in a hypoxia independent
manner, especially in the CSCs. Furthermore, while paclitaxel
and doxorubicin treatment of the MMTV-PyMTmodel of breast
cancer was previously shown to result in increased TAMpresence
in the tumor, hypoxia was not investigated in this setting
(DeNardo et al., 2011). Based on recent findings and the role
of tumor hypoxia in TAM recruitment and promotion of the
alternatively activated, immunosuppressive phenotype, it would
be worthwhile to test inhibitors of HIF targets in combination
with the above chemotherapy drugs in this model to prevent
TAM enrichment and immune evasion following treatment. It
has also recently been demonstrated that estrogen signaling
induces HIF-1α expression by direct binding of the estrogen
receptor (ER)-α to the estrogen response element (ERE) in the
HIF-1α promoter (Yang et al., 2015). HIF-1α expression was
associated with resistance to tamoxifen in in vitro studies and was
correlated with reduced overall survival in ER+ patients treated
with tamoxifen and chemotherapy, correlating HIF-1α with
tamoxifen resistance in patients (Yang et al., 2015). Interestingly,
the CAIX promoter was also found to have an ERE and was
shown to be induced in rat uteri following estrogen treatment
(Yang et al., 2015; Karim et al., 2016). Given the correlation
with HIF-1α and tamoxifen resistance, it would be interesting to
investigate whether CAIX expression is increased in this patient
population. If so, CAIX inhibition might offer a second-line
treatment for ER+ breast cancer patients that have relapsed on
hormone ablation therapy.
CONCLUSION
Therapeutic resistance is a critical determinant of cancer patient
outcome. Identifying biomarkers of response and determinants
of treatment failure is paramount to improving treatment
modalities. The acidic pH and low oxygen tension within
the hypoxic tumor microenvironment of solid tumors poses
a significant hurdle to the efficacy of chemo-, radio- and
immunotherapies. The body of work described here points
to combinatorial treatment approaches designed to eliminate
hypoxic niche cells and improve the response to immunotherapy
and chemotherapy. For example, combining immune checkpoint
inhibitors such as α-PD-1 or α-CTLA-4 with inhibitors of pH
regulatory enzymes such as CAIX and MCT-4 may result in a
reduced response to hypoxia while simultaneously stimulating
the anti-tumor immune response. Furthermore, the application
of CAIX inhibitors in combination with anti-angiogenic agents
has the potential to reduce the cancer stem cell compartment
in the hypoxic niche that is generated as a byproduct of
use of therapies such as bevacizumab and sunitinib. Rational
combinatorial approaches such as these may lead to improved
clinical trial design and ultimately identify effective regimens to
overcome treatment resistance.
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